Increased p85/55/50 Expression and Decreased Phosphotidylinositol 3-Kinase Activity in Insulin-Resistant Human Skeletal Muscle
- Department of Medicine, Division of Endocrinology and Metabolism, University of California, La Jolla, California
- Address correspondence and reprint requests to Jerrold M. Olefsky, MD, University of California at San Diego, Department of Medicine (0673), 225 Stein Clinical Research Bldg., 9500 Gilman Dr., La Jolla, CA 92093. E-mail: jolefsky{at}ucsd.edu
Abstract
Insulin resistance is predominantly characterized by decreased insulin-stimulated glucose uptake into skeletal muscle. In the current study, we have assessed various aspects of the phosphatidylinositol (PI) 3-kinase pathway in skeletal muscle biopsies obtained from normal, obese nondiabetic, and type 2 diabetic subjects, before and after a 5-h insulin infusion. We found a highly significant inverse correlation between in vivo insulin sensitivity (as measured by the glucose infusion rate) and increased protein expression of p85/55/50, protein kinase C (PKC)-θ activity, levels of pSer307 insulin receptor substrate (IRS)-1 and p-Jun NH2-terminal kinase (JNK)-1, and myosin heavy chain IIx fibers. Increased basal phosphorylation of Ser307 IRS-1 in the obese and type 2 diabetic subjects corresponds with decrease in insulin-stimulated IRS-1 tyrosine phosphorylation, PI 3-kinase activity, and insulin-induced activation of Akt and, more prominently, PKC-ζ/λ. In summary, increased expression of the PI 3-kinase adaptor subunits p85/55/50, as well as increased activity of the proinflammatory kinases JNK-1, PKC-θ, and, to a lesser extent, inhibitor of κB kinase-β, are associated with increased basal Ser307 IRS-1 phosphorylation and decreased PI 3-kinase activity and may follow a common pathway to attenuate in vivo insulin sensitivity in insulin-resistant subjects. These findings demonstrate interacting mechanisms that can lead to impaired insulin-stimulated PI 3-kinase activity in skeletal muscle from obese and type 2 diabetic subjects.
- ERK, extracellular signal–related kinase
- IKKβ, inhibitor of κB kinase-β
- IRS, insulin receptor substrate
- JNK, Jun NH2-terminal kinase
- MAP, mitogen-activated protein
- MHC, myosin heavy chain
- PI, phosphatidylinositol
- PKC, protein kinase C
Footnotes
-
- Accepted May 9, 2005.
- Received December 7, 2004.
- DIABETES














